Global PEGylated Proteins Market Size, Share, Opportunities, And Trends By Type (Colony Stimulating Factors, Interferons, Erythropoietin, Recombinant Factor VIII, Monoclonal Antibodies, Others), By Application (Oncology, Gastrointestinal Disorders, Hepatitis, Chronic Kidney Diseases, Multiple Sclerosis, Others), By End Users (Pharmaceutical And Biopharmaceutical Companies, Research Institutes, CROs), And By Geography - Forecasts From 2024 To 2029

The global market for PEGylated proteins is expected to grow at a CAGR of 8.58%, reaching a size of US$1,569.488 million in 2029 from US$882.092 million in 2022.

Factors contributing to the market expansion include the emergence of degenerative and chronic diseases like cancer, kidney diseases, and rheumatoid arthritis, among others, where protein-based treatments are needed, as well as the advantages of PEGylated therapeutic proteins. The increase has been fueled by technological advances that have enabled researchers to create new drugs from proteins they isolate using proteomics and molecular biology techniques.  In the last few years, it has become clear that there is an ever-growing need for recombinant proteins, hormones, enzymes, growth factors, monoclonal antibodies, and many other treatments. Because of the therapeutic benefits, including greater activity and specificity, biologics are now widely available and well-known among the afflicted population.

Global PEGylated Proteins Market Drivers

• Enhanced drug efficacy and stability

The attachment of polyethylene glycol (PEG) chains to proteins improves their stability and solubility, making protein-based therapeutics much more stable and soluble. Given these modifications, the medicine is easily available through biological processes. In addition, there are lower chances that a patient’s body will react to this substance; hence, it will stay in the system longer, increasing the need for it as a medicine.

Moreover, there is an increasing demand for efficient drugs that help fight chronic diseases, including cancer, diabetes, and autoimmune disorders. These drugs have improved pharmacokinetics and reduced dose frequency, leading to market growth. This has resulted in increased use of PEGylated proteins for treating these diseases.

• Rising adoption of consumables

The constant need to develop new products, conduct research, and create better drugs and drug delivery systems leads to a high revenue generation from the continuous consumption of PEGylating consumables like kits and reagents. Additionally, the existence of significant players with a wide range of products promotes segment expansion.

Consumables have been widely adopted due to the benefits and advancements of PEGylation technology and the rising demand for PEGylated goods. PEG's use has increased due to its versatile application in drug development and research projects. Additionally, several businesses that offer customized PEG conjugation services and products constantly use consumables to produce the desired results.

• Increasing demand for Colony-Stimulating Factors (CSFs)

Colony-stimulating Factors (CSFs) are growth factors that bind to receptor proteins, promoting the proliferation and distinction of hematopoietic stem cells into white blood cells. They are used as pharmaceutical agents to boost immune function in cancer patients receiving treatment for low white blood cell counts (neutropenia), which makes them vulnerable to infection. The highest revenue generation in this segment can be attributed to the rising prevalence of various forms of cancer and the therapies that are associated with them. The CSF segment is expected to grow fastest during the forecast period due to the ongoing rise in cancer cases and new product approvals.

The International Agency for Research on Cancer (IARC) projects that by 2040, there will be 16.3 million cancer-related deaths worldwide and 27.5 million new cases of cancer. The burden on the world will come from changes in economic conditions, lifestyle, and aging. Additionally, businesses are hard at work investigating and creating novel or referenced proteins as therapeutic agents.

• High demand from pharmaceutical industries

This is attributable to expanded R&D funding, encouraging government initiatives, and expanded therapeutic product pipelines through various drug discovery and development programs. Additionally, the regulatory support for new product approvals demonstrates the industry dominance of pharmaceutical and biotechnology companies. In May 2022, Amneal Pharmaceuticals, Inc. announced that it had received approval for Fylnetra, a Neulasta biosimilar. Chemotherapy-induced neutropenia among patients is treated with Pegylated GCSF or Granulocyte colony-stimulating factor.

Moreover, the company also declared that they received three biosimilar approvals from the US FDA in 2022 due to this product. The ongoing need for treatments that are both accessible and affordable has pushed healthcare companies to invest heavily in research and development. Furthermore, the high level of market competition and entry barriers for new players have resulted from the patent expiration of innovative PEGylated therapeutics. Some of the major producers of pharmaceutical and biotechnology products in the sector have consolidated their positions in the market due to this tremendous opportunity.

Global PEGylated Proteins Market Geographical Outlook

• North America is witnessing exponential growth during the forecast period

Throughout the forecast period, North America is anticipated to hold a sizable share of the global PEGylated protein market. Several factors contribute to the region’s market share, including the high prevalence of chronic diseases, the presence of key players, the established healthcare infrastructure, and the growing awareness of advanced treatment options among Americans. According to data released in November 2022 by the Canadian Cancer Society, it is anticipated that 2,33,900 Canadians will receive a cancer diagnosis in 2022; the country's aging and expanding population will play a major role in this increase in incidence. Therefore, during the forecast period, the growing prevalence of chronic diseases is anticipated to spur an increase in research and development activity and fuel the regional market growth.

Global PEGylated Proteins Market Key Launches

• In November 2022, Nektar Therapeutics declared that the first preclinical data for NKTR-288 would be presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The purpose of NKTR-288, a novel polyethylene glycol (PEG)-IFN-γ conjugate, is to alter IFN-γ's binding to its substrates and lengthen its signaling period. Cytokine interferon-γ (IFN-γ) is known to trigger cellular antigen presentation and amplify the cytotoxic T-cell response specific to tumor antigens. It is being investigated for potential use in oncology and infectious diseases, among other therapeutic domains.

 

• In February 2022, Merck KGaA announced that it had paid USD 780 million to acquire the CDMO Exelead. The acquisition improved the company's lipid and mRNA capabilities. Exelead is a full-service biopharmaceutical CDMO focusing on PEGylated products and intricate formulations. Additionally, Merck KGaA declared that it will invest more than USD 485.67 (or EUR 500 million) to advance the technologies in the coming years.

Segmentation:

• By Type
  • Colony Stimulating Factors
  • Interferons
  • Erythropoietin
  • Recombinant Factor VIII
  • Monoclonal Antibodies
  • Others
• By Application
  • Oncology
  • Gastrointestinal Disorders
  • Hepatitis
  • Chronic Kidney Diseases
  • Multiple Sclerosis
  • Others
• By End-User
  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes
  • CROs
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GLOBAL PEGYLATED PROTEINS MARKET, BY TYPE

5.1. Introduction

5.2. Colony Stimulating Factors

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.3. Interferons

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

5.4. Erythropoietin

5.4.1. Market Trends and Opportunities

5.4.2. Growth Prospects

5.4.3. Geographic Lucrativeness

5.5. Recombinant Factor VIII

5.5.1. Market Trends and Opportunities

5.5.2. Growth Prospects

5.5.3. Geographic Lucrativeness

5.6. Monoclonal Antibodies

5.6.1. Market Trends and Opportunities

5.6.2. Growth Prospects

5.6.3. Geographic Lucrativeness

5.7. Others

5.7.1. Market Trends and Opportunities

5.7.2. Growth Prospects

5.7.3. Geographic Lucrativeness

6. GLOBAL PEGYLATED PROTEINS MARKET, BY APPLICATION

6.1. Introduction

6.2. Oncology

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Gastrointestinal Disorders

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

6.4. Hepatitis

6.4.1. Market Trends and Opportunities

6.4.2. Growth Prospects

6.4.3. Geographic Lucrativeness

6.5. Chronic Kidney Diseases

6.5.1. Market Trends and Opportunities

6.5.2. Growth Prospects

6.5.3. Geographic Lucrativeness

6.6. Multiple Sclerosis

6.6.1. Market Trends and Opportunities

6.6.2. Growth Prospects

6.6.3. Geographic Lucrativeness

6.7. Others

6.7.1. Market Trends and Opportunities

6.7.2. Growth Prospects

6.7.3. Geographic Lucrativeness

7. GLOBAL PEGYLATED PROTEINS MARKET, BY END-USERS

7.1. Introduction

7.2. Pharmaceutical and Biopharmaceutical Companies

7.2.1. Market Trends and Opportunities

7.2.2. Growth Prospects

7.2.3. Geographic Lucrativeness

7.3. Research Institutes

7.3.1. Market Trends and Opportunities

7.3.2. Growth Prospects

7.3.3. Geographic Lucrativeness

7.4. CROs

7.4.1. Market Trends and Opportunities

7.4.2. Growth Prospects

7.4.3. Geographic Lucrativeness

8. GLOBAL PEGYLATED PROTEINS MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Type

8.2.2. By Application

8.2.3. By End-User

8.2.4. By Country

8.2.4.1. USA

8.2.4.1.1. Market Trends and Opportunities

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Trends and Opportunities

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Trends and Opportunities

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Type

8.3.2. By Application

8.3.3. By End-User

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.1.1. Market Trends and Opportunities

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Trends and Opportunities

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Trends and Opportunities

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Type

8.4.2. By Application

8.4.3. By End-User

8.4.4. By Country

8.4.4.1. UK

8.4.4.1.1. Market Trends and Opportunities

8.4.4.1.2. Growth Prospects

8.4.4.2. Germany

8.4.4.2.1. Market Trends and Opportunities

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Trends and Opportunities

8.4.4.3.2. Growth Prospects

8.4.4.4. Spain

8.4.4.4.1. Market Trends and Opportunities

8.4.4.4.2. Growth Prospects

8.4.4.5. Others

8.4.4.5.1. Market Trends and Opportunities

8.4.4.5.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Type

8.5.2. By Application

8.5.3. By End-User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Trends and Opportunities

8.5.4.1.2. Growth Prospects

8.5.4.2. Israel

8.5.4.2.1. Market Trends and Opportunities

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Trends and Opportunities

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Type

8.6.2. By Application

8.6.3. By End-User

8.6.4. By Country

8.6.4.1. Japan

8.6.4.1.1. Market Trends and Opportunities

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Trends and Opportunities

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Trends and Opportunities

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Trends and Opportunities

8.6.4.4.2. Growth Prospects

8.6.4.5. Others

8.6.4.5.1. Market Trends and Opportunities

8.6.4.5.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Celares GmbH

10.2. Profacgen

10.3. JenKem Technology USA

10.4. Merck KGaA

10.5. QuiaPEG Pharmaceuticals Holding AB

10.6. Belrose Pharma Inc.

10.7. Thermo Fisher Scientific Inc.

10.8. Creative PEGWorks

10.9. NOF Corporation

10.10. Biomatrik Inc

Celares GmbH

Profacgen

JenKem Technology USA

Merck KGaA

QuiaPEG Pharmaceuticals Holding AB

Belrose Pharma Inc.

Thermo Fisher Scientific Inc.

Creative PEGWorks

NOF Corporation

Biomatrik Inc.